Cargando…

CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma

Detalles Bibliográficos
Autores principales:	Tulchiner, Gennadi, Brunner, Andrea, Schmidinger, Manuela, Staudacher, Nina, Orme, Jacob J., Thurnher, Martin, Horninger, Wolfgang, Culig, Zoran, Pichler, Renate
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359430/ https://www.ncbi.nlm.nih.gov/pubmed/33455021 http://dx.doi.org/10.1111/bju.15341

Ejemplares similares

Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Immune-related lichenoid mucocutaneous erosions during anti-PD-1 immunotherapy in metastatic renal cell carcinoma - A case report
por: Lindner, Andrea Katharina, et al.
Publicado: (2018)

HUS1 as a Potential Therapeutic Target in Urothelial Cancer
por: Lindner, Andrea Katharina, et al.
Publicado: (2022)

Lynch Syndrome: Its Impact on Urothelial Carcinoma
por: Lindner, Andrea Katharina, et al.
Publicado: (2021)

Organ-Sparing Surgery in Testicular Tumor: Is This the Right Approach for Lesions ≤ 20 mm?
por: Staudacher, Nina, et al.
Publicado: (2020)

A presumed extragonadal germ cell tumor that turned out to be a gastric cancer—a case report
por: Kafka, Mona, et al.
Publicado: (2021)

Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study
por: Pichler, Renate, et al.
Publicado: (2021)

Long term disease free survival with multimodal therapy in small cell bladder cancer
por: Heidegger, Isabel, et al.
Publicado: (2016)

Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
por: Lindner, Andrea Katharina, et al.
Publicado: (2022)

Urinary UBC Rapid and NMP22 Test for Bladder Cancer Surveillance in Comparison to Urinary Cytology: Results from a Prospective Single-Center Study
por: Pichler, Renate, et al.
Publicado: (2017)

Adenomatoid tumor of the testis mimicking malignant testicular cancer on multiparametric ultrasound
por: Pichler, Renate, et al.
Publicado: (2018)

Do we need repeated CT imaging in uncomplicated blunt renal injuries? Experiences of a high-volume urological trauma centre
por: Lindner, Andrea Katharina, et al.
Publicado: (2022)

High IDO‐1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma
por: Seeber, Andreas, et al.
Publicado: (2018)

Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
por: Pichler, Renate, et al.
Publicado: (2016)

Seasonal Variations in the Diagnosis of Testicular Germ Cell Tumors: A National Cancer Registry Study in Austria
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Renal Cell Carcinoma with Sarcomatoid Features: Finally New Therapeutic Hope?
por: Pichler, Renate, et al.
Publicado: (2019)

Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer
por: Pichler, Renate, et al.
Publicado: (2016)

Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy
por: Martinez-Morilla, Sandra, et al.
Publicado: (2020)

High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer
por: Pichler, Renate, et al.
Publicado: (2018)

Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial
por: Heidegger, Isabel, et al.
Publicado: (2018)

ASCO 2018: highlights of urothelial cancer and prostate cancer
por: Pichler, Renate, et al.
Publicado: (2018)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Predictive and prognostic role of serum neopterin and tryptophan breakdown in prostate cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer—a valid option for cisplatin-unfit patients?
por: Arnold, C. R., et al.
Publicado: (2021)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

MicroRNA-205 inhibits renal cells apoptosis via targeting CMTM4
por: Zhang, Hongxia, et al.
Publicado: (2015)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021)

Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program
por: Heidegger, Isabel, et al.
Publicado: (2015)

Gender-related Outcome in Bladder Cancer Patients undergoing Radical Cystectomy
por: Pichler, Renate, et al.
Publicado: (2017)

CMTM7 recognizes an immune-hot tumor microenvironment and predicts therapeutic response of immunotherapy in breast cancer well
por: Jiang, Xingyu, et al.
Publicado: (2022)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

CMTM8 inhibits the carcinogenesis and progression of bladder cancer
por: GAO, DENGHUI, et al.
Publicado: (2015)

Clinical significance of CMTM4 expression in hepatocellular carcinoma
por: Bei, Chunhua, et al.
Publicado: (2017)

Expression and clinical significance of CMTM1 in hepatocellular carcinoma
por: Song, Xin, et al.
Publicado: (2021)

CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma
por: Li, Ting, et al.
Publicado: (2015)

CMTM5 inhibits renal cancer cell growth through inducing cell-cycle arrest and apoptosis
por: Cai, Bing, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t4btvdago90n8qk8i2kdn93vj1